LGND
Ligand Pharmaceuticals IncorporatedNASDAQHealthcare$199.59+2.01%ClosedMarket Cap: $3.98B
As of 2026-04-06
Valuation
P/E (TTM)
31.98
PEG
0.01
P/B
3.95
P/S
15.15
EV/EBITDA
22.13
DCF Value
$48.79
FCF Yield
1.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.5%
Operating Margin
17.6%
Net Margin
46.4%
ROE
13.9%
ROA
8.0%
ROIC
2.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $59.7M | 143.6% | $20.0M | $44.8M | $2.12 | — |
| FY 2025 | $268.1M | 97.5% | $47.2M | $124.5M | $6.13 | — |
| Q3 2025 | $115.5M | 78.5% | $54.9M | $117.3M | $5.68 | — |
| Q2 2025 | $47.6M | 93.9% | $8.4M | $4.8M | $0.24 | — |
| Q1 2025 | $45.3M | 89.3% | $-36.2M | $-42.5M | $-2.21 | — |
| Q4 2024 | $42.8M | 93.4% | $-9.6M | $-31.1M | $-1.64 | — |
| FY 2024 | $167.1M | 93.4% | $-22.6M | $-4.0M | $-0.22 | — |
| Q3 2024 | $51.8M | 75.9% | $3.1M | $-7.2M | $-0.39 | — |
| Q2 2024 | $41.5M | 136.9% | $-19.1M | $-51.9M | $-2.88 | — |
| Q1 2024 | $31.0M | 64.3% | $3.0M | $86.1M | $4.75 | — |
| Q4 2023 | $28.1M | 94.1% | $-3.4M | $18.2M | $1.03 | — |
| FY 2023 | $131.3M | 73.3% | $11.9M | $52.2M | $2.94 | — |